BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34615717)

  • 1. Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma.
    Thompson CM; Cannon A; West S; Ghersi D; Atri P; Bhatia R; Smith L; Rachagani S; Wichman C; Kumar S; Batra SK
    Clin Cancer Res; 2021 Dec; 27(24):6787-6799. PubMed ID: 34615717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis of pancreatic neoplasms using a novel method of DNA methylation analysis of mucin expression in pancreatic juice.
    Yokoyama S; Kitamoto S; Higashi M; Goto Y; Hara T; Ikebe D; Yamaguchi T; Arisaka Y; Niihara T; Nishimata H; Tanaka S; Takaori K; Batra SK; Yonezawa S
    PLoS One; 2014; 9(4):e93760. PubMed ID: 24714692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas.
    Yokoyama S; Higashi M; Kitamoto S; Oeldorf M; Knippschild U; Kornmann M; Maemura K; Kurahara H; Wiest E; Hamada T; Kitazono I; Goto Y; Tasaki T; Hiraki T; Hatanaka K; Mataki Y; Taguchi H; Hashimoto S; Batra SK; Tanimoto A; Yonezawa S; Hollingsworth MA
    Oncotarget; 2016 Jul; 7(27):42553-42565. PubMed ID: 27283771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125).
    Chauhan SC; Singh AP; Ruiz F; Johansson SL; Jain M; Smith LM; Moniaux N; Batra SK
    Mod Pathol; 2006 Oct; 19(10):1386-94. PubMed ID: 16880776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of mucin expression in pancreatobiliary neoplasms.
    Yonezawa S; Higashi M; Yamada N; Yokoyama S; Goto M
    J Hepatobiliary Pancreat Sci; 2010 Mar; 17(2):108-24. PubMed ID: 19787286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant expression of MUC3 and MUC4 membrane-associated mucins and sialyl Le(x) antigen in pancreatic intraepithelial neoplasia.
    Park HU; Kim JW; Kim GE; Bae HI; Crawley SC; Yang SC; Gum JR; Batra SK; Rousseau K; Swallow DM; Sleisenger MH; Kim YS
    Pancreas; 2003 Apr; 26(3):e48-54. PubMed ID: 12657964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acinar transformed ductal cells exhibit differential mucin expression in a tamoxifen-induced pancreatic ductal adenocarcinoma mouse model.
    Mallya K; Haridas D; Seshacharyulu P; Pothuraju R; Junker WM; Krishn SR; Muniyan S; Vengoji R; Batra SK; Rachagani S
    Biol Open; 2020 Sep; 9(9):. PubMed ID: 32709695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance.
    Andrianifahanana M; Moniaux N; Schmied BM; Ringel J; Friess H; Hollingsworth MA; Büchler MW; Aubert JP; Batra SK
    Clin Cancer Res; 2001 Dec; 7(12):4033-40. PubMed ID: 11751498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and feasibility of mucin expression profiling by qRT-PCR as diagnostic biomarkers in cytology specimens of pancreatic cancer.
    Wiktorowicz M; Mlynarski D; Pach R; Tomaszewska R; Kulig J; Richter P; Sierzega M
    Pancreatology; 2018 Dec; 18(8):977-982. PubMed ID: 30268674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MUC4 expression increases progressively in pancreatic intraepithelial neoplasia.
    Swartz MJ; Batra SK; Varshney GC; Hollingsworth MA; Yeo CJ; Cameron JL; Wilentz RE; Hruban RH; Argani P
    Am J Clin Pathol; 2002 May; 117(5):791-6. PubMed ID: 12090430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
    Zhao L; Zhao H; Yan H
    BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucin expression in endoscopic ultrasound-guided fine-needle aspiration specimens is a useful prognostic factor in pancreatic ductal adenocarcinoma.
    Higashi M; Yokoyama S; Yamamoto T; Goto Y; Kitazono I; Hiraki T; Taguchi H; Hashimoto S; Fukukura Y; Koriyama C; Mataki Y; Maemura K; Shinchi H; Jain M; Batra SK; Yonezawa S
    Pancreas; 2015 Jul; 44(5):728-34. PubMed ID: 25906442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.
    Shi C; Merchant N; Newsome G; Goldenberg DM; Gold DV
    Arch Pathol Lab Med; 2014 Feb; 138(2):220-8. PubMed ID: 24476519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of sialyl-Lewis x on MUC5AC and MUC1 mucins in pancreatic cancer tissues.
    Balmaña M; Duran A; Gomes C; Llop E; López-Martos R; Ortiz MR; Barrabés S; Reis CA; Peracaula R
    Int J Biol Macromol; 2018 Jun; 112():33-45. PubMed ID: 29408556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma.
    Zhang C; Atri P; Nallasamy P; Parte S; Rauth S; Nimmakayala RK; Marimuthu S; Chirravuri-Venkata R; Bhatia R; Halder S; Shah A; Cox JL; Smith L; Kumar S; Foster JM; Kukreja RC; Seshacharyulu P; Ponnusamy MP; Batra SK
    Cancer Lett; 2022 Dec; 551():215922. PubMed ID: 36285687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Semiquantitative immunohistochemistry for mucin (MUC1, MUC2, MUC3, MUC4, MUC5AC, and MUC6) profiling of pancreatic ductal cell adenocarcinoma improves diagnostic and prognostic performance.
    Sierzega M; Młynarski D; Tomaszewska R; Kulig J
    Histopathology; 2016 Oct; 69(4):582-91. PubMed ID: 27165582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy.
    Rachagani S; Torres MP; Kumar S; Haridas D; Baine M; Macha MA; Kaur S; Ponnusamy MP; Dey P; Seshacharyulu P; Johansson SL; Jain M; Wagner KU; Batra SK
    J Hematol Oncol; 2012 Oct; 5():68. PubMed ID: 23102107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer.
    Lahdaoui F; Delpu Y; Vincent A; Renaud F; Messager M; Duchêne B; Leteurtre E; Mariette C; Torrisani J; Jonckheere N; Van Seuningen I
    Oncogene; 2015 Feb; 34(6):780-8. PubMed ID: 24608432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism.
    Zhang JJ; Zhu Y; Xie KL; Peng YP; Tao JQ; Tang J; Li Z; Xu ZK; Dai CC; Qian ZY; Jiang KR; Wu JL; Gao WT; Du Q; Miao Y
    Mol Cancer; 2014 May; 13():130. PubMed ID: 24884523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression.
    Khan S; Sikander M; Ebeling MC; Ganju A; Kumari S; Yallapu MM; Hafeez BB; Ise T; Nagata S; Zafar N; Behrman SW; Wan JY; Ghimire HM; Sahay P; Pradhan P; Chauhan SC; Jaggi M
    Oncogene; 2017 Jan; 36(4):491-500. PubMed ID: 27321183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.